We therefore tested the efficacy of BAY 1895344 together with lorlatinib in two independent genetically modified mouse (GEMM) NB models—Rosa26_Alkal2;Th-MYCN (n = 4) and Alk-F1178S;Th-MYCN (n = 4)49. Here, ALK is linked to neuroblastoma.